May 20, 2019 / 05:00PM GMT
Unidentified Analyst -
Good afternoon, everybody. Thank you for coming to the 2019 UBS Global Healthcare Conference. My name is [Hannah], and I'll be your host for this session. Our next speaker is Dr. Mark Murray, President and CEO of Arbutus Biopharma. There'll be a breakout session held in Uris shortly after this presentation. Thank you.
Mark Joseph Murray - Arbutus Biopharma Corporation - President, CEO & Director
Thank you. Good afternoon, and thank you all for coming today to hear about Arbutus Biopharma. Arbutus is a company that is committed to the development of an effective combination regimen to achieve an HBV cure. We are now more convinced than ever that this combination approach is correct. Thank you. Okay. Arbutus is a publicly traded company, and I will be making forward-looking statements this afternoon.
Arbutus, as I said, has a singular therapeutic focus, the cure of chronic hepatitis B. Chronic hepatitis B is a very large, unmet global need. It is estimated that there are over 250 million infected individuals worldwide. To address this
Arbutus Biopharma Corp at UBS Global Healthcare Conference Transcript
May 20, 2019
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers